Researchers enrolled 40 patients in the study who a multidrug-resistant HIV infection, which could not be treated with other antiviral medications.
After taking ibalizumb for one week, 83 percent of patients experienced a decrease in viral load. After 25 weeks, about half of the patients saw viral load suppression dip below the level of detection. Researchers also found an increase in CD4 T-cells, which plan an important role in the immune system. Only one individual had an adverse event thought to be ibalizumb-related.
While several HIV drugs target the virus, many fail to thoroughly suppress the virus, which leads to drug resistance and allows the disease to progress, according to Futurity. Before the FDA ibalizumb in March 2018, there was not a class of drugs that both targeted HIV and boosted a patient’s immune system.
More articles on clinical leadership and infection control:
Nation’s longest kidney transplant chain surpasses 100 donations
16 nurses pregnant in Arizona hospital’s ICU
How a Kentucky physician uses maggots to treat patients
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.